RxDoctor Payments Data

Kairav Vakil, MD

Cardiovascular Disease · Minneapolis, MNNPI 1467600403

Payments from drug & device makers

$77,159in general payments, 2019–2025

Across 107 payments — averaging $721.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$16K
  • Abbott$16K
  • Alnylam Pharmaceuticals Inc.$15K
  • Bridgebio Pharma, Inc.$15K
  • Novartis$12K
  • Edwards Lifesciences$1K
  • plus $1K from 8 others

What the payments were for

  • Consulting fees$17,62528%
  • Speaking & faculty fees$33,67554%
  • Travel & lodging$7,07211%
  • Food & beverage$3,5856%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,159 in reported general payments places this provider in the 80th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$71,339
Medicare patients
614
Services billed
1,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis41$2,088,193
VyndaqelTafamidis Meglumine15$324,716
EntrestoSacubitril/Valsartan179$192,592
EliquisApixaban137$164,480
JardianceEmpagliflozin89$110,236
XareltoRivaroxaban95$109,289
Repatha SureclickEvolocumab58$41,466
FarxigaDapagliflozin Propanediol28$31,812
VascepaIcosapent Ethyl13$7,569
Metoprolol Succinate318$6,609
Atorvastatin Calcium254$3,747
Rosuvastatin Calcium205$3,328
Carvedilol248$2,908
Isosorbide Mononitrate ErIsosorbide Mononitrate106$2,891
Torsemide92$2,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$11,861$192,592179 claims
Boehringer IngelheimJardiance$50$110,23689 claims
AstraZenecaFarxiga$16,335$31,81228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →